Biopharmaceutical company Gilead Sciences is bringing on Omnicom Group to manage PR for its HIV portfolio, according to a source familiar with the matter. 

A Gilead spokesperson declined to comment on agency roster changes, but said, “Gilead partners with different agencies to further build on the expertise of our in-house PR and advocacy teams, working with agencies that help us address the needs of the businesses and patients we support.”

The agencies within Omnicom PR Group include FleishmanHillard, Ketchum, MMC and Porter Novelli. An Omnicom spokesperson could not be reached for comment on which agencies will work on Gilead’s HIV business. 

BCW, which has worked on comms for the drugmaker’s HIV division, is continuing to work with Gilead in other capacities, a source familiar with the matter said. A BCW spokesperson could not be reached for comment. 

BCW was pitching HIV-related content on behalf of Gilead as recently as April. The firm, which is in the process of merging with fellow WPP PR agency Hill & Knowlton to form a combined shop known as Burson, worked on a campaign Gilead ran with Jason Rodriguez, the star of FX’s show Pose, on an HIV-prevention event. 

Omnicom Group’s PR firms posted an organic revenue decrease of 1.1% in Q1 to $390.3 million.

Gilead develops medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. The company operates in more than 35 countries, with headquarters in Foster City, California.

Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis, known as PrEP, to help reduce HIV infections and the first long-acting injectable HIV treatment medication, according to a Gilead statement. Gilead’s HIV portfolio includes the treatments Biktarvy, Truvada and Viread. 

Higher sales of HIV, oncology and liver-disease treatments were credited for Gilead’s 5% increase in revenue in Q1 to $6.7 billion. HIV product sales rose 4% to $4.3 billion.

Biktarvy generated $2.9 billion in sales in Q1, an increase of 10% over the same period of the previous year. 

This article originally appeared on PRWeek US.